BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. The Company has two operating segments or business units: the Products business unit and the CDMO Services business unit. In identifying these operating segments, management generally follows the Company's service lines representing its main products and services. The Products Business Unit - Nutraceuticals: Research, development, manufacturing, marketing and sales of science-based health and wellness nutraceutical solutions which are manufactured and sold as dietary supplements, functional food and beverages. The CDMO Services Business Unit - comprising a Contract Development and Manufacturing Operation that offers pharmaceuticals, cosmeceuticals, nutraceuticals, and nutritions.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$0.907 – $1.41
Volume86,670
Market cap$31M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for BHST.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for BHST.
Recent news
Company coverage with links to the original publishers.
BioHarvest Sciences Inc. (BHST) reported a Q3 loss of $0.15 per share, beating EPS estimates but missing revenue expectations with $7.87 million versus the consensus estimate. The company's stock has declined 66.3% year-to-date, significantly underperforming the S&P 500's 11.3% gain. BHST received a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
MiNK Therapeutics reported a Q3 loss of $0.5 per share, beating consensus estimates of $0.66 loss by 24.24%. The company posted $0.2 million in revenues, surpassing estimates by 33.33% compared to zero revenues a year ago. However, shares have underperformed the market, down 10.2% year-to-date versus the S&P 500's 9.9% gain. The stock holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
ImmunityBio (IBRX) reported a quarterly loss of $0.10 per share, missing consensus estimates of $0.08, representing a -25% earnings surprise. Revenue of $48.84 million also missed expectations by 19.6%, though it grew from $32.06 million year-over-year. Despite the miss, the stock has surged 336.1% YTD versus the S&P 500's 7.8% gain. The company maintains a Zacks Rank #2 (Buy) rating based on favorable estimate revision trends ahead of the earnings release.
OTC Markets Group reported the performance of its OTCQX and OTCQB indexes in Q4 2024. The OTCQX Composite Index, OTCQX Billion+ Index, and OTCQX Dividend Index all declined, while the OTCQX Banks Index and OTCQX U.S. Index saw gains. Several companies moved from the OTC markets to major exchanges during the quarter.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.